Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

NARAHARA Hiroyuki; IISHI Hiroyasu; IMAMURA Hiroshi; TSUBURAYA Akira; CHIN Keisho; IMAMOTO Haruhiko; ESAKI Taito; FURUKAWA Hiroshi; HAMADA Chikuma; SAKATA Yuh

Art

J-GLOBAL ID：201102258024543010 Reference number：11A0789578

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

ランダム化フェーズIIIスタディによる進行胃癌に対する第一次化学療法(GC0301/TOP-002)としてのイリノテカン+S-1とS-1単独投与の有効性と安全性の比較

Publisher site Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=11A0789578&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0789578&from=J-GLOBAL&jstjournalNo=L7803A") }}

Author (10)： , , , , , , , , ,
Material：
Volume： 14 Issue： 1 Page： 72-80 Publication year： 2011
JST Material Number： L7803A ISSN： 1436-3291 Document type： Article
Article type：原著論文 Country of issue： Japan (JPN) Language： ENGLISH (EN)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0789578&from=J-GLOBAL&jstjournalNo=L7803A") }}

Clinical application of antitumor(=antineoplastic)drugs , Drug therapy(=pharmacotherapy)for tumors , Tumors(=neoplasms)of digestive system

Reference (35)：

1. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan 2007. Available from URL http://ganjoho.ncc.go.jp/ public/statistics/backnumber/2007_en.html. Accessed June 21, 2010.
2. Maruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, Katai H, et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006,9:51-66.
3. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18:2648-57.
4. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folimc acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19:1450-7.
5. Ajani JA, Moiseyenko VM, Tjulandin S, Majilis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatm compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25:3205-9.

ｍore...

, , , , , , ,

Return to Previous Page